{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:37:14Z","timestamp":1784864234403,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.urology.2018.06.022","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T22:43:08Z","timestamp":1530139388000},"page":"143-149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Postfinasteride Syndrome"],"prefix":"10.1016","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2542-8882","authenticated-orcid":false,"given":"Wesley R.","family":"Baas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Butcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aye","family":"Lwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Herberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Delfino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Althof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias S.","family":"Kohler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin T.","family":"McVary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2018.06.022_bib0001","unstructured":"Questions and Answers: Finasteride Label Changes. U.S. Department of Health & Human Services, 2012. (Accessed 6\/15\/15, at http:\/\/www.fda.gov\/Drugs\/DrugSafety\/InformationbyDrugClass\/ucm299754.htm)"},{"key":"10.1016\/j.urology.2018.06.022_bib0002","series-title":"Whitehouse Station","year":"2010"},{"key":"10.1016\/j.urology.2018.06.022_bib0003","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1155\/2012\/530121","article-title":"The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases","volume":"2012","author":"Azzouni","year":"2012","journal-title":"Adv Urol"},{"key":"10.1016\/j.urology.2018.06.022_bib0004","year":"2008","journal-title":"Research Triangle Park NC, USA: GlaxoSmithKline;"},{"key":"10.1016\/j.urology.2018.06.022_bib0005","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.juro.2011.01.074","article-title":"Update on AUA guideline on the management of benign prostatic hyperplasia","volume":"185","author":"McVary","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2018.06.022_bib0006","year":"2014"},{"key":"10.1016\/j.urology.2018.06.022_bib0008","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1515\/hmbci-2014-0025","article-title":"5 alpha-reductase inhibitors alter steroid metabolism and may contribute to insulin resistance, diabetes, metabolic syndrome and vascular disease: a medical hypothesis","volume":"20","author":"Traish","year":"2014","journal-title":"Horm Mol Biol Clin Investig"},{"key":"10.1016\/j.urology.2018.06.022_bib0009","doi-asserted-by":"crossref","first-page":"E1397","DOI":"10.1210\/jc.2014-1395","article-title":"5alpha-reductase type 1 modulates insulin sensitivity in men","volume":"99","author":"Upreti","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.urology.2018.06.022_bib0010","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1473-2165.2005.40218.x","article-title":"Psychological aspects of hair disease","volume":"4","author":"Grimalt","year":"2005","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.urology.2018.06.022_bib0011","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6904-6-7","article-title":"Finasteride induced depression: a prospective study","volume":"6","author":"Rahimi-Ardabili","year":"2006","journal-title":"BMC Clin Pharmacol"},{"key":"10.1016\/j.urology.2018.06.022_bib0012","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1473-2165.2010.00533.x","article-title":"Finasteride-induced depression: new insights into possible pathomechanisms","volume":"9","author":"Romer","year":"2010","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.urology.2018.06.022_bib0013","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/s-0030-1249095","article-title":"Finasteride treatment inhibits adult hippocampal neurogenesis in male mice","volume":"43","author":"Romer","year":"2010","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.urology.2018.06.022_bib0014","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1111\/jsm.12269","article-title":"Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious\/depressive symptomatology","volume":"10","author":"Melcangi","year":"2013","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2018.06.022_bib0015","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1346-8138.2002.tb00200.x","article-title":"Depression circumstantially related to the administration of finasteride for androgenetic alopecia","volume":"29","author":"Altomare","year":"2002","journal-title":"J Dermatol"},{"key":"10.1016\/j.urology.2018.06.022_bib0016","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1743-6109.2010.02157.x","article-title":"Adverse side effects of 5alpha-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients","volume":"8","author":"Traish","year":"2011","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2018.06.022_bib0017","first-page":"222","article-title":"Finasteride treatment and neuroactive steroid formation","volume":"110","author":"Duskova M","year":"2009","journal-title":"Prague Med Rep"},{"key":"10.1016\/j.urology.2018.06.022_bib0018","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1530\/eje.0.1450669","article-title":"Neurosteroid metabolism in the human brain","volume":"145","author":"Stoffel-Wagner","year":"2001","journal-title":"Eur J Endocrinol Eur Feder Endocr Soc"},{"key":"10.1016\/j.urology.2018.06.022_bib0019","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.pbb.2006.06.016","article-title":"Neurosteroids, neuroactive steroids, and symptoms of affective disorders","volume":"84","author":"Dubrovsky","year":"2006","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.urology.2018.06.022_bib0020","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1111\/j.1743-6109.2012.02846.x","article-title":"Persistent sexual side effects of finasteride: could they be permanent?","volume":"9","author":"Irwig","year":"2012","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2018.06.022_bib0021","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.4088\/JCP.12m07887","article-title":"Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects","volume":"73","author":"Irwig","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.urology.2018.06.022_bib0022","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/1557988314538445","article-title":"Persistent sexual, emotional, and cognitive impairment post-finasteride: a survey of men reporting symptoms","volume":"9","author":"Ganzer","year":"2015","journal-title":"Am J Men Health"},{"key":"10.1016\/j.urology.2018.06.022_bib0023","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1001\/jamadermatol.2015.36","article-title":"Adverse event reporting in clinical trials of finasteride for androgenic alopecia: a meta-analysis","volume":"151","author":"Belknap","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.urology.2018.06.022_bib0024","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3109\/09546634.2013.813011","article-title":"The efficacy and safety of 5alpha-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride","volume":"25","author":"Gupta","year":"2014","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.urology.2018.06.022_bib0025","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/phar.1837","article-title":"Persistent sexual dysfunction with finasteride 1 mg taken for hair loss","volume":"36","author":"Guo","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.urology.2018.06.022_bib0026","first-page":"i4823","article-title":"Risk of erectile dysfunction associated with use of 5-alpha reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink","volume":"354","author":"Hagberg","year":"2016","journal-title":"BMJ (Clin Res Ed)"},{"key":"10.1016\/j.urology.2018.06.022_bib0027","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1111\/j.1743-6109.2007.00563.x","article-title":"Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon?","volume":"4","author":"Mondaini","year":"2007","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2018.06.022_bib0028","year":"2012"},{"key":"10.1016\/j.urology.2018.06.022_bib0029","unstructured":"Conner MW D-CC, Green LC, Armstrong SR, Taniguchi C, Tashijan AH, and Golan DE. Drug toxicity. principles of pharmacology: the pathophysiologic basis of drug therapy. 3 ed. 2011:56-70."}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429518305909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429518305909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T19:42:46Z","timestamp":1720381366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429518305909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":28,"alternative-id":["S0090429518305909"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2018.06.022","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Postfinasteride Syndrome","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2018.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}